Biocon’s board has approved the acquisition of equity shares in Biocon Biologics Limited (BBL) from Mylan Inc., Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II, and Activ Pine LLP. The transaction involves issuing new equity shares and a cash payment, totaling up to ₹6,950 Crores. The aim is to simplify the corporate structure and enhance shareholder value.
Equity Share Acquisition in Biocon Biologics
Biocon’s board of directors has given the green light to acquire equity shares of Biocon Biologics Limited (BBL) from various entities. The announcement was made on December 6, 2025, after a board meeting.
Transaction Details
The acquisition will involve shares held by:
- Mylan Inc.
- Serum Institute Life Sciences Private Limited
- Tata Capital Growth Fund II
- Activ Pine LLP
The consideration will be discharged through a combination of issuing new equity shares via preferential allotment and a cash component.
Preferential Issue
The company will issue 17,12,79,553 equity shares to the selling shareholders on a preferential basis. The issue price has been determined as ₹405.78 per equity share, aggregating up to ₹6,950 Crores for consideration other than cash.
Fund Raising and Commercial Paper Issuance
The board also approved raising funds up to ₹4,500 Crores through various means, including equity shares, non-convertible debt instruments, or a combination thereof. Additionally, commercial papers for an amount up to ₹1,800 Crores will be issued to manage cash remittance to Mylan in the interim.
Rationale and Objectives
The acquisition aims to simplify the corporate structure, enable a larger balance sheet, and improve capital allocation strategy. The company believes this integration will deliver operational synergies and maximize value for all stakeholders. The acquisition is expected to be completed by March 31, 2026, subject to shareholder and regulatory approvals.
BBL Turnover
The turnover for Biocon Biologics Limited (BBL) for the last three financial years is as follows:
- FY23: ₹20,923.83 Mn
- FY24: ₹30,932.50 Mn
- FY25: ₹29,543 Mn
Source: BSE
